NCT01325428 - Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions

Breast Neoplasms

Interventions

DRUG

Afatinib once daily (OD)

Patient to receive afatinib monotherapy until progression of their disease

DRUG

Vinorelbine Weekly

Patients additionally receive vinorelbine weekly on disease progression on afatinib monotherapy

Trial Locations (16)

1200.89.10001 Boehringer Ingelheim Investigational Site, Los Angeles

1200.89.10005 Boehringer Ingelheim Investigational Site, Durham

1200.89.61002 Boehringer Ingelheim Investigational Site, East Bentleigh

1200.89.61003 Boehringer Ingelheim Investigational Site, Perth

1200.89.85201 Boehringer Ingelheim Investigational Site, Hong Kong

1200.89.82001 Boehringer Ingelheim Investigational Site, Seoul

1200.89.82002 Boehringer Ingelheim Investigational Site, Seoul

1200.89.66002 Boehringer Ingelheim Investigational Site, Bangkok

1200.89.66004 Boehringer Ingelheim Investigational Site, Bangkok

1200.89.66003 Boehringer Ingelheim Investigational Site, Chiang Mai

1200.89.66001 Boehringer Ingelheim Investigational Site, Hat-Yai, Songkhla

1200.89.21601 Boehringer Ingelheim Investigational Site, Aryanah

1200.89.21602 Boehringer Ingelheim Investigational Site, Sousse

1200.89.44002 Boehringer Ingelheim Investigational Site, Bournemouth

1200.89.44001 Boehringer Ingelheim Investigational Site, London

1200.89.44003 Boehringer Ingelheim Investigational Site, London